Primary Care Physicians May Be Ordering More Pap Smears Than Necessary(11/13/2009) Researchers from the National Institutes of Health have reported that primary care physicians overuse Pap smear testing and are not following current recommendations. The details of this study appeared in the November 3, 2009 issue of the Annals of Internal Medicine.
Vaccination for HPV in Females Associated with a Decline in Genital Warts in Females and Males(10/29/2009) Researchers from Australia have reported a decline in the number of cases of genital warts in women and men since the initiation of quadrivalent vaccination to prevent human papillomavirus (HPV) infection. The details of this study appeared in an early on-line publication in Sexually Transmitted Infections on October 16, 2009.
Knowledge Deficits Limit Use of HPV Vaccine in Young Women(10/29/2009) Researchers from Roswell Park Cancer Institute, Upstate Medical University and the State University of New York at Buffalo have reported that knowledge and risk perceptions among college students limits vaccination for human papillomavirus (HPV). The details of this study appeared in an early on-line publication in Sexually Transmitted Infections on October 19, 2009.
HPV Vaccination Not Cost-effective for Women over 30 Years of Age(10/28/2009) Researchers from the Harvard School of Public Health have reported that human papillomavirus vaccination for prevention of cervical cancer is not cost-effective in women between the ages of 35 and 45 years. The details of this report appeared in the October 20, 2009 issue of the Annals of Internal Medicine.
CDC Panel Rejects Routine Vaccination of Boys with Gardasil® but Approves use for Preventing Genital Warts(10/26/2009) On September 9, 2009, a U.S. FDA advisory panel voted for approval of the use of Gardasil® for the prevention of genital warts in males ages nine through 16. The age range was based on safety data for this age group. However, another U.S. FDA advisory panel, on 10/21/2009, voted against the routine use of Gardasil for vaccination of all young boys.
Sentinel Node Biopsy Is a Minimally-invasive, Effective Method for Determining Spread of Cervical Cancer(6/10/2009) Researchers from France have reported that the majority of women with cervical cancer can safely undergo sentinel node biopsy instead of full pelvic lymph node dissection to determine the spread of their disease, thereby avoiding the complications associated with the more invasive procedure. The details of this study were reported at the 2009 annual meeting of the American Society of Clinical Oncology in Orlando, Florida, on May 31.
Robotically-assisted Hysterectomy Appears Effective for Cervical Cancer(11/24/2008) Researchers from the University of North Carolina have reported that robotically-assisted hysterectomy (RAH) in patients with early-stage cervical cancer is at least as effective as traditional open radical hysterectomy (ORH) and produces fewer complications. The details of this study appeared in the October 2008 issue of the American Journal of Obstetrics and Gynecology.
HPV Vaccine, Cervarix™, not Therapeutic in Women with Preexisting Infection(8/22/2007) Researchers affiliated with the Costa Rican HPV Vaccine Trial have reported that women who are positive for HPV DNA, do not benefit from Cervarix (GlaxoSmithKline) a vaccine against HPV 16/18 L1 virus-like particle. The details of this study appeared in the August 15, 2007 issue of the Journal of the AmericanMedical Association.
Sentinel Node Biopsy Is a Minimally-invasive, Effective Method for Determining Spread of Cervical Cancer(6/10/2009) Researchers from France have reported that the majority of women with cervical cancer can safely undergo sentinel node biopsy instead of full pelvic lymph node dissection to determine the spread of their disease, thereby avoiding the complications associated with the more invasive procedure. The details of this study were reported at the 2009 annual meeting of the American Society of Clinical Oncology in Orlando, Florida, on May 31.
Gemzar® Added to Chemoradiation Improves Survival in Locally Advanced Cervical Cancer(6/9/2009) Researchers involved in an International multicenter study have reported that the addition of Gemzar® (gemcitabine) to the standard therapy of Platinol® (cisplatin) and concurrent radiation significantly improved survival in women with Stage IIB-IVA cervical cancer. The details of this study were presented at the 2009 annual meeting of the American Society of Clinical Oncology in Orlando, Florida on May 31.
Robotically-assisted Hysterectomy Appears Effective for Cervical Cancer(11/24/2008) Researchers from the University of North Carolina have reported that robotically-assisted hysterectomy (RAH) in patients with early-stage cervical cancer is at least as effective as traditional open radical hysterectomy (ORH) and produces fewer complications. The details of this study appeared in the October 2008 issue of the American Journal of Obstetrics and Gynecology.
Progress on Development of Vaccines to Prevent and Treat HPV Associated Cervical Cancer(5/2/2003) In a conference titled
Development of Therapeutic Cancer Vaccines held in Los Angeles on April 27-29, 2003, Ian Fraxer from Brisbane, Australia reviewed the progress of efforts to develop vaccines against human papilloma (HPV) for prevention of infection, prevention of cervical cancer, and for therapy of established cervical cancer
Metastatic / Stage IVB
Recurrent
Avastin® Shows Promise in Treatment of Cervical Cancer(3/6/2009) Researchers affiliated with the Gynecologic Oncology Group have reported that Avastin® (bevacizumab) has significant activity for the treatment of persistent or recurrent squamous cell carcinoma of the cervix. These results were published in the March 1, 2009 issue of the Journal of Clinical Oncology.
Neulasta® on First Day of Chemotherapy May Be More Convenient for Gynecologic Cancers(3/18/2008) Researchers from the University of Alabama have reported that the administration of Neulasta® (pegfilgrastim) on the first day of chemotherapy among women with gynecologic cancers may be as effective as and more convenient than second-day administration. These results were recently reported at the 2008 annual Society of Gynecologic Oncologists meeting.
Avastin® Combination Has Activity in Heavily Pretreated Cervical Cancer(11/13/2006) Researchers from Washington University have reported that Avastin (bevacizumab) in combination with 5-FU or Xeloda® (capecitabine) is active in women with heavily pretreated, recurrent cervical cancer.
Progress Reported on Human Papilloma Virus (HPV) Vaccine(4/30/2003) Dr. John Neefe, from Stress Biotechnologies, reported progress on CoVal™, a Human Papilloma Virus vaccine at a conference titled
Development of Therapeutic cancer Vaccines held in Los Angeles April 27-29. This meeting was sponsored by the John Wayne Cancer Institute, the International Association of Biologicals, and the Royal Society of Medicine.
Patient Home
